Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 3751–3800 of 76264
Upon Mr. Reese's assumption of this role, Matt Kaplan, who was appointed President and Chief Executive Officer of the Company effective March 4, 2022, concluded his service as the Company's President and Chief Executive Officer.
On May 1, 2026, the Company's board of directors appointed Jason W. Reese to serve as the Company’s Chief Executive Officer effective immediately following the filing of the Company’s Form 10-Q for the period ended March 31, 2026.
On May 4, 2026, the Company's Board of Directors (the “Board”) appointed Mark A. Caylor as a Class II Director, effective immediately, to serve for a term expiring at the annual meeting of stockholders in 2029 and until his successor is elected and qualified.
Daniel Hoffman, Matthew Burns, James Shekerdemian and Francis Beaudette (the " New Directors ") were appointed to the board of directors of the Company
Samuel Sayegh was appointed as Chairman of the Company’s Board
Daniel Hoffman, Matthew Burns, James Shekerdemian and Francis Beaudette (the " New Directors ") were appointed to the board of directors of the Company
Daniel Hoffman, Matthew Burns, James Shekerdemian and Francis Beaudette (the " New Directors ") were appointed to the board of directors of the Company
Daniel Hoffman, Matthew Burns, James Shekerdemian and Francis Beaudette (the " New Directors ") were appointed to the board of directors of the Company
Under the Settlement Agreement, the Inscobee Parties have agreed to secure the resignation or removal of Mr. Koo.
Following Mr. Akright’s resignation, Eric Sherb, who has been serving as Co-Chief Financial Officer, will continue to serve as the Company’s Chief Financial Officer.
Effective as of April 28, 2026, Richard Akright advised the Company that he was resigning from his position as Co-Chief Financial Officer of urban-gro, Inc. (the “Company”), with such resignation becoming effective on such date.
On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.
Seth H. Meyer, age 57, the Company's Chief Financial Officer since March 2019, will transition from his role as Chief Financial Officer and was appointed President of the Company.
Andrew Olson, age 43, was appointed Chief Financial Officer and Head of Corporate Development, succeeding Mr. Meyer in the role of Chief Financial Officer.
on May 4, 2026, following Mr. Barbieri's appointment as COO, Eddie Lazarus will no longer serve as the Company's Business Development Officer but will continue to serve as the Company's Chief Legal Officer.
On April 15, 2026, the Company appointed Frank Barbieri as Chief Operating Officer ("COO") and principal operating officer, effective as of May 4, 2026.
the Board of the Company appointed Jacob Saour as a member of the Board, effective immediately.
Karen Macleod and Peter Poli submitted their resignations as members of the Board of Directors of the Company
Karen Macleod and Peter Poli submitted their resignations as members of the Board of Directors of the Company
the Board of the Company appointed Denver Smith as a member of the Board, effective immediately.
the Board of the Company appointed Matthew Powalski as a member of the Board, effective immediately.
the Board of the Company appointed Kyle Kidd as a member of the Board, effective immediately.
On May 1, 2026, the Company’s board of directors appointed Lorenzo A. Flores, the Company’s Chief Financial Officer as Principal Accounting Officer of the Company.
On April 24, 2026, during a telephonic discussion with members of the Board of Directors (the “Board”) of Sentient Brands Holdings Inc. (the “Company”), George Furlan informed the Board of his resignation, effective April 24, 2026, from his positions as Interim Chief Executive Officer of the Company and as a member of the Board.
Effective May 1, 2026, and until such time as a new Chief Executive Officer is appointed, the Board designated Serge Knazev to serve as the Company’s acting principal executive officer for purposes of Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder, including the execution of certifications, attestations and other documents required to be signed by the principal executive officer in connection with the Company’s periodic and current reports filed under the Exchange Act.
On April 24, 2026, during a telephonic discussion with members of the Board of Directors (the “Board”) of Sentient Brands Holdings Inc. (the “Company”), George Furlan informed the Board of his resignation, effective April 24, 2026, from his positions as Interim Chief Executive Officer of the Company and as a member of the Board.
On April 28, 2026, the board of directors (the “Board”) of Streamex Corp. (the “Company”) appointed Mr. Mitchell Young Williams, the Company’s Chief Investment Officer, to serve as a non-independent director of the Board
the Board of Directors (the “Board”) of the Company appointed Laura C. Holson as the interim Chief Financial Officer and Treasurer of the Company, effective May 29, 2026.
Effective as of May 8, 2026, the Company's Board of Directors has appointed Julia Brau Donnelly, the Company's Chief Financial Officer, as principal accounting officer.
On April 30, 2026, Andrea Acosta, the Company's Chief Accounting Officer, submitted her resignation to the Company to pursue another opportunity, effective May 8, 2026.
On March 30, 2026, and in connection with the closing of the acquisition contemplated by the Purchase Agreement and the Board Election Agreement entered on April 1, 2026 (the “ Board Election Agreement ”), the Board of Directors of Parent appointed Steve Girardin as a Class III Director, effective as of the closing, with a term expiring at the annual stockholder meeting in 2029, and under certain circumstances if Steve Girardin leaves the Board prior to such annual meeting, to appoint Dave Girardin as his replacement through the 2029 annual meeting.
Mr. Bakas, who currently serves as President of Renewable Fuels of Ameresco will step down from this role at Ameresco and become the Chief Executive Officer of the Joint Venture.
On May 4, 2026, the Board of Directors (the "Board") of BARK, Inc. (the "Company") announced the appointment of James Gagne as a member of the Board, effective immediately, as a Class A director for a term expiring at the Company's 2028 annual meeting of stockholders and until his successor is duly elected and qualified.
approved the appointment of Paul Keel to fill the new director position, effective as of July 1, 2026
On May 4, 2026, after more than twenty years of service, Steve Odland informed the Company that he has decided not to stand for reelection to the Board of Directors at the Company’s 2026 Annual Meeting of Shareholders in September.
On April 13, 2026, Irving Minnaker resigned from the Board of Directors (the "Board") of Cycurion, Inc. (the "Company") and from any and all offices that he holds with the Company, effective as from February 14, 2026.
On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company’s Board of Directors (the “Board”) . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
On May 4, 2026, the Board agreed to appoint Michal Fisher as an independent member of the Company’s Board.
On May 4, 2026, Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc.
On May 1, 2026, the Board of Directors (the “Board”) of VisionWave Holdings, Inc. (the “Company”) approved the appointment of Atara Dzikowski as Vice President of Mergers and Acquisitions.
On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).
Mr. Russell succeeds Bruce Tindal who has served as the board’s chair since 2023 and retired from the board on April 29, 2026.
The First Bancorp (Nasdaq: FNLC), parent company of First National Bank, announced on Wednesday, April 29, 2026, that its board of directors has elected Cornelius “Connie” Russell as the board’s chair.
On April 29, 2026, Robert R. Dillard, KB Home ’ s Executive Vice President and Chief Financial Officer, resigned from his position, effective May 8, 2026.
On April 27 , 2026, the Board of Directors of Cisco appointed Nichlas A. Fink to succeed Ms. Wong as Senior Vice President and Chief Accounting Officer of Cisco effective May 20, 2026.
On April 27, 2026, M. Victoria Wong notified Cisco Systems, Inc. ("Cisco") of her decision to retire as Senior Vice President and Chief Accounting Officer of Cisco effective May 19, 2026.
as of the Effective Time, the Burke & Herbert board of directors appointed current LNKB directors Diane Poillon and Kristen Snyder to the board of the surviving corporation as the LNKB Continuing Directors.
as of the Effective Time, the Burke & Herbert board of directors appointed current LNKB directors Diane Poillon and Kristen Snyder to the board of the surviving corporation as the LNKB Continuing Directors.
Under the Agreement, Ms. Crosby will continue to serve as Executive Chair of the Bank and the Company until June 30, 2026 (the "Transition Date"), at which time she will continue to serve the Bank and the Company as a non-executive Chair of the Boards of Directors and will no longer maintain an employment position with the Bank or the Company.
Sarah A. Mussetter notified Red Robin Gourmet Burgers, Inc. (the “Company”) of her resignation as Chief Legal Officer and Secretary of the Company, to be effective as of May 15, 2026.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.